Skip to content

Study · Not a test of the peptide alone · 2025

3 results

Improvement in Chronic Atrophic Gastritis After Treatment with Zinc L-Carnosine.

De Bastiani R, Fassan M, Businello G, Tursi A

The American journal of case reports20 Nov 2025Cited by 1 (Europe PMC)

PMID41264559 (opens in a new tab)PMCIDPMC12683967 (opens in a new tab)DOI10.12659/ajcr.950553 (opens in a new tab)PepBankPUB-41264559
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking L-carnosine.

  1. 01HumanNot a test of L-carnosine aloneCase report or seriesEfficacy outcome

    In two patients with chronic atrophic gastritis, zinc L‑carnosine treatment accompanied clinically significant improvement in dyspeptic symptoms.

    In plain wordsIn two patients with chronic atrophic gastritis, zinc L‑carnosine treatment accompanied improved digestive symptoms.

    Peptide
    L-carnosine
    Outcome
    DecreaseDyspeptic symptoms
    Study

    n = 2

    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    Clinically significant improvement was observed not only in dyspeptic symptoms but also in histologic features of CAG.
    2 context sentences
    Summary · context
    CASE REPORT We report 2 cases of CAG - 1 secondary to autoimmune gastritis and the other secondary to H. pylori infection - that were managed with oral zinc L-carnosine 39.5 mg twice daily for at least 12 months due to persistent dyspeptic symptoms.
    Summary · context
    Both patients underwent endoscopic and histologic reassessment at least 12 months after therapy initiation.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  2. 02HumanNot a test of L-carnosine aloneCase report or seriesEfficacy outcome

    In two patients with chronic atrophic gastritis, zinc L‑carnosine treatment accompanied clinically significant improvement in histologic features.

    In plain wordsIn two patients with chronic atrophic gastritis, zinc L‑carnosine treatment accompanied improved stomach tissue findings.

    Peptide
    L-carnosine
    Outcome
    Direction not reportedHistologic features of CAG
    Study

    n = 2

    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    Clinically significant improvement was observed not only in dyspeptic symptoms but also in histologic features of CAG.
    2 context sentences
    Summary · context
    CASE REPORT We report 2 cases of CAG - 1 secondary to autoimmune gastritis and the other secondary to H. pylori infection - that were managed with oral zinc L-carnosine 39.5 mg twice daily for at least 12 months due to persistent dyspeptic symptoms.
    Summary · context
    Both patients underwent endoscopic and histologic reassessment at least 12 months after therapy initiation.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

  3. 03HumanNot a test of L-carnosine aloneCase report or seriesEfficacy outcome

    In two patients with chronic atrophic gastritis, changes in pepsinogen I, pepsinogen II and gastrin 17 indicated improved gastric function during zinc L‑carnosine treatment.

    In plain wordsIn two patients, changes in pepsinogen I, pepsinogen II and gastrin 17 indicated improved stomach function during zinc L‑carnosine treatment.

    Peptide
    L-carnosine
    Outcome
    Direction not reportedGastric function indicated by pepsinogen I, pepsinogen II and gastrin 17
    Study

    n = 2

    Outcome group
    Gastrointestinal protection · Gastrointestinal

    Source sentences

    Summary
    The beneficial effects of long-term zinc L-carnosine treatment were further supported by improved gastric function, as indicated by changes in pepsinogen I, pepsinogen II, and gastrin 17 levels.
    2 context sentences
    Summary · context
    CASE REPORT We report 2 cases of CAG - 1 secondary to autoimmune gastritis and the other secondary to H. pylori infection - that were managed with oral zinc L-carnosine 39.5 mg twice daily for at least 12 months due to persistent dyspeptic symptoms.
    Summary · context
    Both patients underwent endoscopic and histologic reassessment at least 12 months after therapy initiation.

    In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.